Amicus Therapeutics Net Income 2010-2022 | FOLD

Amicus Therapeutics net income from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Amicus Therapeutics Annual Net Income
(Millions of US $)
2021 $-250
2020 $-277
2019 $-356
2018 $-349
2017 $-284
2016 $-200
2015 $-132
2014 $-69
2013 $-60
2012 $-49
2011 $-44
2010 $-55
2009 $-7
Amicus Therapeutics Quarterly Net Income
(Millions of US $)
2022-09-30 $-33
2022-06-30 $-62
2022-03-31 $-85
2021-12-31 $-83
2021-09-30 $-50
2021-06-30 $-51
2021-03-31 $-66
2020-12-31 $-71
2020-09-30 $-64
2020-06-30 $-52
2020-03-31 $-89
2019-12-31 $-90
2019-09-30 $-62
2019-06-30 $-85
2019-03-31 $-120
2018-12-31 $-78
2018-09-30 $-159
2018-06-30 $-62
2018-03-31 $-50
2017-12-31 $-69
2017-09-30 $-112
2017-06-30 $-48
2017-03-31 $-55
2016-12-31 $-59
2016-09-30 $-47
2016-06-30 $-51
2016-03-31 $-44
2015-12-31 $-43
2015-09-30 $-38
2015-06-30 $-27
2015-03-31 $-24
2014-12-31 $-21
2014-09-30 $-17
2014-06-30 $-15
2014-03-31 $-16
2013-12-31 $-12
2013-09-30 $-15
2013-06-30 $-15
2013-03-31 $-17
2012-12-31 $-10
2012-09-30 $-16
2012-06-30 $-9
2012-03-31 $-13
2011-12-31 $-9
2011-09-30 $-10
2011-06-30 $-13
2011-03-31 $-13
2010-12-31 $-15
2010-09-30 $-15
2010-06-30 $-11
2010-03-31 $-13
2009-12-31 $33
2009-09-30 $-13
2009-06-30 $-14
2009-03-31 $-12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.700B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00